Pear Therapeutics announced formulary availability of its commercial products at OptumRx, Inc., the innovative pharmacy care services business of Optum, Inc. Pear’s commercial products include the Prescription Digital Therapeutics (PDTs) reSET and reSET-O for the treatment of substance use disorder and opioid use disorder, respectively, and Somryst  for the treatment of chronic insomnia. OptumRx will offer and administer standard pharmacy benefit coverage for reSET, reSET-O and Somryst for members who choose to add the products to their formularies.

OptumRx manages the prescription drug benefits of commercial, Medicare, Medicaid and other government health plans, as well as those of employers and unions. This formulary availability makes it possible for organisations to opt-in to coverage, making it easier for patients to access evidence-based treatment anytime and anywhere via PDTs.

“We are pleased to team with OptumRx and their customers to provide patients with access to innovative, FDA-authorized PDTs,” said Julia Strandberg, Chief Commercial Officer of Pear Therapeutics. “PDTs are designed to offer patients safe and effective treatments via their mobile devices when and where they need it most. Pear continues to expand access to PDTs by adding reSET, reSET-O, and Somryst to formularies across the United States.”

PDTs are a new therapeutic class that uses software to directly treat disease. Like traditional medicines, PDTs are developed in a GMP-compliant environment, tested in randomized controlled trials demonstrating safety and effectiveness, evaluated and authorized by regulators like FDA, and used under the supervision of a prescribing clinician. Unlike traditional medicines, PDTs are designed to collect real-world data for use by prescribing clinicians and for population health management by payors and health systems. Pear recently released publications showing the potential for improved health outcomes and decreased treatment costs for patients using reSET-O